Stephens & Co. Reiterates Overweight on Cytek Biosciences, Maintains $6 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetReiterationAnalyst Ratings
Stephens & Co. analyst Mason Carrico reiterates Cytek Biosciences (NASDAQ:CTKB) with a Overweight and maintains $6 price target.
Stephens & Co. analyst Mason Carrico reiterates Cytek Biosciences (NASDAQ:CTKB) with a Overweight and maintains $6 price target.